MedTrace Logo

Effects of ITB Myofascial Release on Symptoms Associated With Knee OA.

NCT06109038 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-12-17

No results posted yet for this study

Summary

The aim of this randomized controlled trial is to determine the effects of ITB myofascial release with graston technique on symptoms associated with knee Osteoarthritis for reducing pain, enhancing knee range of motion and decrease functional disability.

Conditions

Interventions

OTHER

Conventional PT + ITB release with graston technique

An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins . Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).

OTHER

Conventional PT

Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Maria khalid, MS-OMPT · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06109038 on ClinicalTrials.gov